Please assess the completion status of the following clinical trial:

Trial Title: Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Histologically-confirmed breast cancer (operable, locally advanced or inflammatory)~2. Age less than 70 years~3. Female patient~4. Tumor size 2 cm at ultrasound examination.~5. ER-negative tumors defined according to immunohistochemistry (i.e. \< 10% of positive cells after immunostaining).~6. Multifocal and multicentric breast tumors are allowed if all foci are ER-negative.~7. Fixed and frozen samples from the primary tumor, obtained before treatment with epirubicin, must be available for evaluation of biological markers (topo II alpha gene and protein, HER-2 gene, p-53 gene, oligonucleotides microarrays).~8. Written informed consent before study registration.~9. Performance status 0 or 1 (ECOG scale)~10. Normal CBC, hepatic and renal functions~11. Normal left ventricular ejection fraction by echocardiography or muga scan~12. Negative pregnancy test for all women of childbearing potential. Patients of childbearing potential must implement adequate non-hormonal measures to avoid pregnancy during treatment.~Exclusion Criteria:~1. Metastatic breast cancer~2. Serious medical conditions like:~   1. congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled arrhythmias.~  2. history of significant neurologic or psychiatric disorders~  3. active uncontrolled infection~  4. active peptic ulcer, unstable diabetes mellitus~3. Concomitant contralateral invasive breast cancer~4. Concurrent treatment with hormonal replacement therapy~5. Concurrent treatment with any other anti-cancer therapy~6. Previous treatment with anthracyclines for breast cancer

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).